Please login to the form below

Not currently logged in
Email:
Password:

Janssen Biotech signs $975m deal to buy into new oral cancer drug

US biopharmaceutical company Pharmacyclics could receive almost $1bn if all milestones are met

Janssen Biotech has bought into a new investigational cancer drug in a deal that could be worth almost $1bn to Pharmacyclis, the US biopharmaceutical company that discovered it.

Bruton tyrosine kinase inhibitor PCI-32765 is an oral drug that is currently in phase I and II trials for a range of B-cell malignancy disorders including chronic lymphocytic leukaemia and non-Hodgkin's lymphoma.

Both markets are expected to see strong growth over the next few years, with analysts at Research and Markets forecasting chronic lymphocytic leukaemia will be worth $2.2bn by 2020 and non-Hodgkin's lymphoma to reach $11.9 billion by 2017

PCI-32765 is also being developed for a number of other indications, including multiple myeloma, mantle cell lymphoma and diffuse large B-cell lymphoma.

William Hait, global therapeutic head of oncology for Janssen, said: "The agreement with Pharmacyclics is an opportunity to bring a new form of oral therapy to patients with B-cell malignancies. PCI-32765 is an innovative compound, with broad applicability and the potential to help a large number of patients with B-cell malignancies."

Pharmacyclics will receive up to $975m for the deal, including an upfront payment of $150m and further development and regulatory milestone payments worth up to $825m.

In return Janssen and Pharmacyclics will split profits equally and share development and commercialisation costs.

Each company will take the lead on development for specific indications, with development costs shared on a 40 per cent (Pharmacyclics) to 60 per cent (Janssen) basis.

PCI-32765 is a small molecule that works by inhibiting the Bruton's tyrosine kinase (Btk), an essential element of the B-cell antigen receptor (BCR) signalling pathway.

BCR signalling is a critical pathway required for tumour expansion and proliferation, and PCI-32765 exerts its anti-tumour function by blocking BCR signalling and thereby inducing cell death.

The companies will collaborate on the development of PCI-32765 for oncology and other indications but their agreement does not include the drug's potential use to treat inflammation or immune mediated conditions.

9th December 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics